肺癌分子病理学的进展：技术进步与临床实践
Update in Lung Cancer Molecular Pathology: Technological Advances and Clinical Practice.
作者信息
Graziano Paolo, Rossi Giulio
机构信息
Services Department, Pathology Unit, Scientific Institute for Research and Health Care (IRCCS) "Casa Sollievo della Sofferenza", Viale Cappuccini 1, 71013 San Giovanni Rotondo, Italy.
Services Department, Pathology Unit, Fondazione Poliambulanza Hospital Institute, Via Bissolati 57, 25124 Brescia, Italy.
出版信息
Cancers (Basel). 2023 Jul 27;15(15):3812. doi: 10.3390/cancers15153812.
Abstract
This Special Issue of eleven articles, including six original works and five reviews, demonstrates the modern heterogenous approach to lung cancer by means of various methodologies from international experts from various countries [...].
摘要
本期特刊包含11篇文章，其中有6篇原创作品和5篇综述，展示了来自不同国家的国际专家通过各种方法对肺癌采用的现代多学科方法[……]
相似文献
1
Update in Lung Cancer Molecular Pathology: Technological Advances and Clinical Practice.肺癌分子病理学的进展：技术进步与临床实践
Cancers (Basel). 2023 Jul 27;15(15):3812. doi: 10.3390/cancers15153812.
2
News from the Breath Analysis Summit 2011.2011年呼吸分析峰会新闻。
J Breath Res. 2012 Jun;6(2):020201. doi: 10.1088/1752-7155/6/2/020201. Epub 2012 May 23.
3
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
4
The inaugural Qatar Critical Care Conference with its Qatar Medical Journal Special Issue - An important milestone.首届卡塔尔重症监护会议及其《卡塔尔医学杂志》特刊——一个重要的里程碑。
Qatar Med J. 2019 Nov 7;2019(2):1. doi: 10.5339/qmj.2019.qccc.1. eCollection 2019.
5
Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update.分子检测指南：选择肺癌患者接受靶向酪氨酸激酶抑制剂治疗：美国临床肿瘤学会对美国病理学家学院/国际肺癌研究协会/分子病理学会临床实践指南更新的认可。
J Clin Oncol. 2018 Mar 20;36(9):911-919. doi: 10.1200/JCO.2017.76.7293. Epub 2018 Feb 5.
6
An International Consensus on Actions to Improve Lung Cancer Survival: A Modified Delphi Method Among Clinical Experts in the International Cancer Benchmarking Partnership.国际改善肺癌生存行动计划共识：国际癌症基准合作组织临床专家的改良德尔菲法。
Cancer Control. 2022 Jan-Dec;29:10732748221119354. doi: 10.1177/10732748221119354.
7
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区，服用抗叶酸抗疟药物的人群中，叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
8
Hypoxia and Cancer: From Bench to Bedside.缺氧与癌症：从实验室到临床
Cancers (Basel). 2023 Apr 26;15(9):2478. doi: 10.3390/cancers15092478.
9
Recent Advances in Pathology: the 2021 Annual Review Issue of The Journal of Pathology.病理学新进展：《病理学杂志》2021 年年鉴特刊。
J Pathol. 2021 Jul;254(4):303-306. doi: 10.1002/path.5687.
10
Special Issue of () "Purinergic P2 Receptors: Structure and Function".()“嘌呤能 P2 受体：结构与功能”专刊。
Int J Mol Sci. 2020 Dec 31;22(1):383. doi: 10.3390/ijms22010383.
本文引用的文献
1
NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023.美国国立综合癌症网络（NCCN）指南见解：非小细胞肺癌，2023年第2版
J Natl Compr Canc Netw. 2023 Apr;21(4):340-350. doi: 10.6004/jnccn.2023.0020.
2
Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer.KRAS 突变型非小细胞肺癌的治疗策略
Cancers (Basel). 2023 Mar 7;15(6):1635. doi: 10.3390/cancers15061635.
3
Advances in the Molecular Landscape of Lung Cancer Brain Metastasis.肺癌脑转移分子格局的进展
Cancers (Basel). 2023 Jan 24;15(3):722. doi: 10.3390/cancers15030722.
4
Robust Performance of the Novel Research-Use-Only Idylla GeneFusion Assay Using a Diverse Set of Pathological Samples with a Proposed 1-Day Workflow for Advanced NSCLC Evaluation.新型仅用于研究的Idylla基因融合检测在多种病理样本中的稳健性能及用于晚期非小细胞肺癌评估的拟议一日工作流程
Cancers (Basel). 2022 Dec 31;15(1):292. doi: 10.3390/cancers15010292.
5
Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature.监测晚期表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）患者血浆及其他液体活检中的游离DNA（cfDNA）：一项初步研究及文献综述
Cancers (Basel). 2021 Oct 28;13(21):5403. doi: 10.3390/cancers13215403.
6
Extracellular Vesicles in Lung Cancer: Prospects for Diagnostic and Therapeutic Applications.肺癌中的细胞外囊泡：诊断与治疗应用前景
Cancers (Basel). 2021 Sep 14;13(18):4604. doi: 10.3390/cancers13184604.
7
Exosomes in Lung Cancer: Actors and Heralds of Tumor Development.肺癌中的外泌体：肿瘤发展的参与者与先驱
Cancers (Basel). 2021 Aug 27;13(17):4330. doi: 10.3390/cancers13174330.
8
Preliminary Report on Computed Tomography Radiomics Features as Biomarkers to Immunotherapy Selection in Lung Adenocarcinoma Patients.计算机断层扫描影像组学特征作为肺腺癌患者免疫治疗选择生物标志物的初步报告
Cancers (Basel). 2021 Aug 7;13(16):3992. doi: 10.3390/cancers13163992.
9
Biomarkers and Gene Signatures to Predict Durable Response to Pembrolizumab in Non-Small Cell Lung Cancer.预测非小细胞肺癌对帕博利珠单抗持久反应的生物标志物和基因特征
Cancers (Basel). 2021 Jul 29;13(15):3828. doi: 10.3390/cancers13153828.
10
Clinical and Molecular Features of Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors (TKIs): Predictive and Prognostic Role of Co-Mutations.接受酪氨酸激酶抑制剂（TKIs）治疗的表皮生长因子受体（EGFR）突变阳性非小细胞肺癌（NSCLC）患者的临床和分子特征：共突变的预测和预后作用
Cancers (Basel). 2021 May 17;13(10):2425. doi: 10.3390/cancers13102425.
Zotero 插件